by François Briand | Dec 4, 2023 | 2023
iLeads BMS publishes a new manuscript about its novel FXR agonist in Physiogenex’s obese MASH hamster and mouse models – review the manuscript here. If you wish to evaluate your novel therapies using Physiogenex CRO services and models, feel free to...
by François Briand | Nov 23, 2023 | 2023
Physiogenex will be presenting its innovative obese MetALD hamster model at the 7th Obesity and NASH Summit in Boston, MA, USA, Nov. 27-29, 2023. This unique preclinical model will be presented during the poster session on November the 28th at 2:30pm by Dr. François...
by François Briand | Nov 6, 2023 | 2023
Physiogenex will be presenting a novel obese NASH hamster model of MetALD (Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Alcohol-Associated Liver Disease) at the AASLD Liver Meeting in Boston, USA, Nov. 10-14th, 2023. This unique model will be...
by François Briand | Nov 6, 2023 | 2023
Physiogenex is a proud sponsor of the Hanson Wade 7th IPF Summit to be held in Boston, Sept. 19-21, 2023: On Sept.20th, Dr. François Briand, our Director of Research and Business Development, will be presenting Bleomycin-induced IPF in diet-induced obese (DIO) mice, a...
by François Briand | Aug 29, 2023 | 2023
Physiogenex will be presenting a new NASH hamster study at the 10th Aging Research and Drug Discovery (ARDD) Meeting in Copenhagen, Denmark, August 28th-September 1st, 2023. The poster presentation, entitled “Semaglutide induces weight loss, reduces insulin...
by François Briand | Jun 17, 2023 | 2023
Physiogenex will be presenting a new DIABETIC NASH HFpEF hamster study at the 83rd Scientific Sessions of the American Diabetes Association in San Diego, CA, USA, June 23-26, 2022. The poster (#1595-P), entitled “Empagliflozin Improves Nephropathy and Heart Failure...
